Cisplatin News and Research RSS Feed - Cisplatin News and Research

Study shows experimental treatment not superior to standard therapy for head and neck cancer

Study shows experimental treatment not superior to standard therapy for head and neck cancer

Results of the largest Canadian clinical trial to date comparing standard treatment for locally advanced squamous cell head and neck cancer with an experimental treatment, did not show the new treatment is superior. [More]
New treatment prevents chemotherapy-induced hearing loss in children with cancer

New treatment prevents chemotherapy-induced hearing loss in children with cancer

Investigators from Children's Hospital Los Angeles and 37 other Children's Oncology Group hospitals in the U.S. and Canada have determined that sodium thiosulfate prevents cisplatin-induced hearing loss in children and adolescents with cancer. [More]
New treatment with therapeutic short interfering RNA could help thwart cancer

New treatment with therapeutic short interfering RNA could help thwart cancer

In the fight against cancer, doctors dish out combination-blows of surgery, chemotherapy and other drugs to beat back a merciless foe. Now, scientists have taken early steps toward adding a stinging punch to clinicians' repertoire. [More]
Combination treatment can reduce tumor's resistance to chemotherapy in ovarian cancer

Combination treatment can reduce tumor's resistance to chemotherapy in ovarian cancer

Treating ovarian cancer with platinum-based chemotherapy drugs such as cisplatin is initially very effective, with about four out of five patients responding favorably. However, most of these patients quickly become resistant to chemotherapy and may not respond as well to this standard treatment for the disease. [More]
Scientists discover new option for treating malignant pleural mesothelioma

Scientists discover new option for treating malignant pleural mesothelioma

Researchers at the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital have discovered a new option for treating malignant pleural mesothelioma. [More]
Cold medication could suppress spread of bladder cancers

Cold medication could suppress spread of bladder cancers

Hokkaido University researchers have discovered that a nonsteroid anti-inflammatory drug used for treating colds suppresses the spread of bladder cancers and reduces their chemoresistance in mice, raising hopes of a future cure for advanced bladder cancers. [More]
Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen. [More]
Pitt researchers show how repair protein finds structural errors in DNA

Pitt researchers show how repair protein finds structural errors in DNA

Researchers at the University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute have demonstrated how Rad4, a protein involved in DNA repair, scans the DNA in a unique pattern of movement called "constrained motion" to efficiently find structural faults in DNA. [More]
IMRT linked to reduced xerostomia and feeding tube dependency in oropharyngeal cancer patients

IMRT linked to reduced xerostomia and feeding tube dependency in oropharyngeal cancer patients

Radiation therapy is the main treatment modality in the management of head and neck cancer. [More]
IMRT reduces risk of side effects, improves quality of life for endometrial and cervical cancer patients

IMRT reduces risk of side effects, improves quality of life for endometrial and cervical cancer patients

Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience better quality of life when treated with intensity-modulated radiation therapy (IMRT) than with conventional radiation therapy (RT), according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

The monoclonal antibody necitumumab has been approved since February 2016 for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for this condition. [More]
First-line nivolumab promising in advanced NSCLC

First-line nivolumab promising in advanced NSCLC

Phase I results published in the Journal of Clinical Oncology suggest that nivolumab, either given alone or alongside platinum-based doublet chemotherapy, could have a role in the first-line treatment of advanced non-small-cell lung cancer. [More]
Chemoradiotherapy and post-operative chemotherapy provide similar outcomes in gastric cancer patients

Chemoradiotherapy and post-operative chemotherapy provide similar outcomes in gastric cancer patients

Post-operative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared to post-operative chemotherapy in patients with gastric cancer who have already undergone pre-operative chemotherapy, according to phase III data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. [More]
Study examines role of HOX genes in ovarian cancer resistance

Study examines role of HOX genes in ovarian cancer resistance

A new UK study has identified a gene signature that predicts poor survival from ovarian cancer. The study also identified genes which help the cancer develop resistance to chemotherapy - offering a new route to help tackle the disease. [More]
Cisplatin-based chemotherapy may lead to hearing loss in many testicular cancer survivors

Cisplatin-based chemotherapy may lead to hearing loss in many testicular cancer survivors

Many testicular cancer survivors experience hearing loss after cisplatin-based chemotherapy, according to researchers at Indiana University. [More]
ERCC2 validated as chemotherapy response biomarker in bladder cancer

ERCC2 validated as chemotherapy response biomarker in bladder cancer

Somatic mutations in the helicase-encoding ERCC2 gene are associated with response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive urothelial bladder carcinoma. [More]
Researchers aim to protect kidneys while improving cisplatin's efficacy against cancer

Researchers aim to protect kidneys while improving cisplatin's efficacy against cancer

Cisplatin is a common, powerful chemotherapy agent used for a wide range of cancers such as breast, ovarian and lung, that in a handful of days can also permanently damage or destroy patients' kidneys. [More]
Whole-exome sequencing can help characterize genetic alterations for commonly used bladder cancer cell lines

Whole-exome sequencing can help characterize genetic alterations for commonly used bladder cancer cell lines

Much of basic cancer research is based on studies with cultured cancer cells. However, the usefulness of these studies greatly depends on how accurately these cancer cells grown in a dish represent human tumors. [More]
Drug candidate delivered by plant-virus-based carrier shows promise for triple-negative breast cancer

Drug candidate delivered by plant-virus-based carrier shows promise for triple-negative breast cancer

In a pair of firsts, researchers at Case Western Reserve University and Massachusetts Institute of Technology have shown that the drug candidate phenanthriplatin can be more effective than an approved drug in vivo, and that a plant-virus-based carrier successfully delivers a drug in vivo. [More]
Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Researchers at the University of Cincinnati College of Medicine have found that adding increasing doses of an approved Type 2 diabetes drug, metformin, to a chemotherapy and radiation treatment regimen in head and neck cancer patients is not well tolerated if escalated too quickly, but allowing slower escalation could be beneficial. [More]
Advertisement
Advertisement